Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 28Lymphoma 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Breast Neoplasms 22Multiple Myeloma 21Lymphoma, Large B-Cell, Diffuse 21Carcinoma, Non-Small-Cell Lung 21Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hodgkin Disease 15Lymphoma, T-Cell, Cutaneous 13Glioblastoma 13Leukemia, Lymphocytic, Chronic, B-Cell 12Brain Neoplasms 12Recurrence 11Neuroblastoma 11Myelodysplastic Syndromes 11Mycosis Fungoides 11Lymphoma, B-Cell, Marginal Zone 11Leukemia 11Burkitt Lymphoma 11Neoplasms 10Sezary Syndrome 9Congenital Abnormalities 9Prostatic Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Squamous Cell Carcinoma of Head and Neck 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms, Plasma Cell 7

Interventions

Azacitidine 5venetoclax 4Specimen Handling 3Nivolumab 2regorafenib 1midostaurin 1iadademstat 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Tacrolimus 1Methotrexate 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
GATA2 Deficiency × Vorinostat × Clear all
NCT01522976 2026-04-30

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡